Therefore, this study evaluates the effect and safety of VMAT2 inhibitors (tetrabenazine, deutetrabenazine, and valbenazine) and dopamine stabilizers (pridopidine and ordopidine) compared to oral placebo, based on improvements in chorea symptoms, disease progression, and treatment safety, considering the types and frequency of adverse events to inform clinical practice and guide long-term treatment decisions for Huntington’s disease chorea. The gene discussed is SLC18A2; the disease is choreatic disease.